NeoGenomics

Phase A — Understand the business

Lens 1 · Company Overview

NeoGenomics runs a network of CAP-accredited, CLIA-certified cancer-testing labs — Fort Myers FL (HQ-area), Aliso Viejo & Carlsbad CA, Durham NC, Ramsey NJ, Houston TX, plus a Cambridge UK sample-processing lab (ISO 15189) — with ~2,500 FTEs including ~135 MDs/PhDs. It listed on Nasdaq as NEO; it is a Nevada corporation.

How it makes money. Two engines under one reported segment:

1. Clinical testing (the large majority of revenue) — technical-component ("tech-only") and professional-component (interpretation) services sold to community pathology/oncology practices, hospital labs, reference labs, and academic centers. Revenue is recognized at a point in time when results are delivered to the ordering physician, booked net of implicit price concessions (est. of what will actually be collected after payer denials/discounts). Menu spans karyotyping, FISH, flow cytometry, IHC/digital pathology, single-gene molecular, NGS panels (PanTracer Tissue / PanTracer LBx / Neo Comprehensive / NeoTYPE), and MRD (RaDaR ctDNA + flow-based).
2. Pharma / "non-clinical" services — biomarker analysis, assay development, clinical-trial sample testing (a CRO-style unit-of-service model), plus oncology data solutions (licensing de-identified oncology data to pharma/biotech). Explicitly not a trial sponsor — sponsors retain study design and regulatory responsibility.

Payment terms / concentration. Client-direct billing dominates (71% of net revenue 2025), then commercial insurance (16%) and Medicare/other government (13%); self-pay ~0%. No single client >10% of revenue in 2023–2025 — genuinely diversified on the client side, but heavily exposed to payer/reimbursement policy and to the ~29% of revenue that is third-party (commercial + government) reimbursed. Client-direct billing being the majority means the biggest counterparty risk is hospitals/practices paying their bills, not a single payer.

Verdict on the model: a reimbursement-driven volume business with real scale and a broad menu, but structurally a services business (point-in-time revenue, price-concession estimation, payer denials) — closer to a lab than to a software/platform. The growth optionality is entirely in mix-shift toward higher-value NGS + MRD.

Lens 2 · Supply Chain

Named stakeholders along the chain (names or it didn't happen):

• Upstream inputs → NeoGenomics: sequencing instruments/reagents and consumables. The 10-K doesn't name reagent vendors, but the economics disclose reagent/probe/supply concentration risk and reagent purchase commitments of $11.6M through 2028 ($5.3M/yr 2026–2027). In this industry the practical single-source dependencies are Illumina (NGS sequencing chemistry — the field's dominant chokepoint) and instrument/antibody/probe suppliers (e.g., Roche/Ventana, Leica, Thermo Fisher). Management flags that "other manufacturers may discontinue or recall testing products" as a named risk.
• NeoGenomics (the conversion step): specimen accessioning → wet-lab (extraction, library prep, sequencing, FISH/flow/IHC) → interpretation by staff MDs/PhDs → report delivered via LIMS/CRM. Turnaround time is the stated competitive weapon.
• Logistics chokepoint: specimen transport. Shipping-carrier "performance issues, service interruptions, or price increases" are called out as a distinct risk — a real single-point-of-failure for a lab whose product is a physical specimen that must arrive fast.
• Downstream end customers: community-based pathologists & oncologists, hospital pathology labs, reference labs, academic centers, and pharma sponsors (the CRO/data side). End-of-chain "buyer" for reimbursement is Medicare/CMS + commercial payers (UnitedHealth, etc.), which sit behind the client-direct-billing layer.

Chokepoints that matter: (1) reagent/sequencing supply (Illumina-style concentration), (2) specimen logistics/carriers, (3) reimbursement rate-setting by CMS/payers — the true bottleneck on unit economics, since a test with no coverage is a test that isn't ordered.

Lens 3 · Competitive Advantages (moats)

Honest read: the moat is a narrow-to-medium services moat, not a structural one.

• Comprehensive oncology-only menu + community channel. The differentiator management leans on: a one-stop molecular menu so samples don't get split across labs, plus a 10-region national direct sales force trained in oncology, plus ~135 MDs/PhDs for interpretation/consult. For a community pathologist who can't build molecular in-house, NeoGenomics is a non-competitive partner (it does the tech-only piece and lets them keep the professional read) — this is a real relationship/switching-cost advantage at the practice level.
• Turnaround time as the repeat-order flywheel — plausible but not proprietary.
• IP: patents expiring 2025–2045; RaDaR (via the 2021 Inivata acquisition) is the crown-jewel MRD tech, and NeoGenomics just won the Natera patent challenge (both Natera patents ruled invalid; litigation fully resolved Dec 2025) — removing an existential legal cloud over RaDaR/InVisionFirst.

Bargaining power (who needs whom): Weak with payers — CMS and commercial insurers set the price; NeoGenomics is a price-taker, and the whole industry is one LCD/rate cut away from margin compression. Moderate with suppliers — reagent concentration means limited leverage over Illumina-class vendors. Moderate with clients — diversified (no >10% client) and sticky at the practice level, but competing against far larger balance sheets.

Competitors named in the filing: legacy labs Quest Diagnostics, LabCorp, ARUP; specialized/growth names Guardant Health, Natera, Exact Sciences, Caris Life Sciences, Tempus AI, Myriad Genetics. NeoGenomics is out-resourced by the legacy labs and out-narrated (on liquid biopsy/AI) by the growth names — it is the "stuck-in-the-middle" competitor, defending on breadth + community relationships.

Lens 4 · Segments

Hard constraint honored: segments.csv is empty and the company reports a single operating segment (CEO = CODM, who manages to consolidated net loss). There is no product-line or geographic segment P&L disclosed. Substantially all revenue and tangible long-lived assets are US. So the only ``-grade disaggregation is by payer, plus the management-provided clinical-vs-non-clinical color.

Net revenue by payer (in $000s):

Trend + cause: Total revenue grew +11.6% (2024) → +10.1% (2025) → +11.1% (Q1-26 YoY) — a steady low-double-digit grower. The most important mix signal is commercial insurance revenue accelerating (+24% YoY in Q1-26 to $30.9M vs +18% for FY25), consistent with the shift toward higher-value, insurance-reimbursed NGS/MRD tests. Management's own product color (from the Q1-26 release): clinical revenue +14% YoY, NGS revenue +26% YoY in Q1-26 — the growth is disproportionately in the NGS/molecular tail while the "non-clinical" pharma-services line is a drag (macro clinical-trial slowdown). The absence of a segment P&L is itself an analytical limitation — you cannot see the true margin of the NGS growth engine vs. the legacy FISH/flow base.

---

Phase B — Measure performance

Lens 5 · Earnings Result (latest print: Q1-2026, reported 2026-04-28)

The headline: a beat, an accelerating top line, and a raised revenue guide — layered over persistent GAAP losses.

• Revenue $186.7M, +11.1% YoY (vs $168.0M Q1-25); described as a beat vs consensus. Drivers: test-volume growth, mix-shift to higher-value tests, strategic reimbursement initiatives, + Pathline acquisition, partially offset by weaker non-clinical/pharma revenue.
• Gross profit $80.9M, 43.3% margin (vs 43.6% Q1-25) — margin flat-to-slightly-down on higher supplies + comp, a recurring theme.
• GAAP net loss $(17.1)M, EPS $(0.13) — a material improvement from $(25.9)M / $(0.20) in Q1-25.
• Adjusted EBITDA $9.0M (vs $7.1M), adj. diluted EPS ~$0.01. Note the gap: reported EBITDA (unadjusted) was $(1.8)M — the $9.0M "adjusted" number adds back $9.6M of SBC plus acquisition/legal items. SBC is ~5% of revenue and recurring, so "adjusted EBITDA" flatters the picture (see Lens 10).
• Guidance (raised). FY2026 revenue guide raised to $797–803M; FY2026 adj. EBITDA reiterated at $55–57M (+27–31% YoY). The revenue raise + EBITDA hold is the crux of the current bull narrative: operating leverage is supposed to arrive in 2026.
• Balance-sheet flags (see Lens 10 for the forensic detail): cash $146.1M (down from $159.6M at YE25); operating cash flow $(8.1)M in Q1-26 (a use of cash, though far better than $(25.3)M in Q1-25). Accounts receivable $159.2M at YE25 vs revenue $727M — DSO ~80 days, in line for a payer-mix lab.
• Market reaction / what's priced in: the stock closed $7.42 on 3/31/2026 but has since tripled to ~$15.16 (7/2/2026) — so the market re-rated hard into and after this print + the guide raise + the RaDaR-ST launch. The unusual thing vs the company's own history: 2025 was a guidance-cut year (Aug 2025 Q2 slashed FY25 rev $753M→$720-726M, EBITDA $55-58M→$41-44M, and the stock fell 20%+ on the day). Q1-26 is the "credibility rebuild" print; the burden of proof for the rest of 2026 is high.

Lens 6 · Earnings Calls (sentiment trend)

transcripts/ is empty on the shelf, so this is ``-labeled from call coverage.

• Q1-2026 call (Apr 2026): tone is confident/recovery — "strong revenue growth and strategic" execution, raised revenue guide, heavy emphasis on therapy selection + MRD as the growth vectors and the RaDaR ST launch as the marquee catalyst; NGS +26%, clinical +14%; sales-force expansion 140 → 165 reps by year-end.
• Q4-2025 call (Feb 2026): transitional — new-CEO (Tony Zook) framing, RaDaR-ST clinical launch teased for February, Natera-litigation win as de-risking, but also the Trapelo disposal + InVisionFirst-Lung impairment as clean-up.
• Mid-2025 (Q2-25) call: the low point — guidance cut, $45M net loss quarter, credibility hit.

Shift over time: from "missing and cutting" (mid-2025) → "cleaning up and rebasing" (early 2026) → "executing and raising" (Q1-26). The recurring phrases that have appeared: "therapy selection," "MRD," "$20B addressable market," "launch excellence," "community channel." The thing they've largely stopped saying: the aggressive Project-Pearl-era top-line targets that got cut. Sentiment is genuinely improving, but off a low base and led by a CEO with <18 months in the seat.

Lens 7 · Comps

Peer table — NeoGenomics vs the two comp clusters it straddles. Multiples are `` with source/date; where I could not source a metric I write n/a rather than fabricate. ROE is meaningless/negative for the loss-making names (equity is being eroded by losses), so I flag it rather than invent a "5-yr avg ROE."

The single most important comps read: the market values NeoGenomics at ~3.0x EV/Sales — essentially a legacy-lab multiple (Quest 2.7x, LabCorp ~2.1x), NOT a precision-oncology growth multiple (Guardant 21x, Natera ~14x, Tempus ~8x). This is the entire bull/bear crux. Bulls say NEO is mispriced — same MRD/NGS TAM as Guardant/Natera at a fraction of the multiple. Bears say the multiple is correct — NEO grows ~11% (vs Guardant/Tempus 30–80%), loses money, carries an OIG overhang, and lacks a proprietary-platform narrative, so it deserves the lab multiple, not the growth multiple. EV/EBITDA is not meaningful (524x on tiny adjusted EBITDA); the name trades on EV/Sales and the FCF-inflection story.

Lens 8 · Stock-Price Catalysts (moves >5% over the cycle)

Mostly ``. The pattern is unusually clean: this stock trades on guidance credibility and reimbursement/pipeline events, far more than on any single quarter's revenue beat.

• Aug 2025 — down ~20.2% on the Q2-25 guidance cut (FY25 rev $753M→$720-726M; adj EBITDA $55-58M→$41-44M) + $45.1M quarterly net loss. This was the defining drawdown — it drove the stock to its 52-wk low of $4.72.
• Jan 2025 — CEO succession announced (Chris Smith to retire; Tony Zook to take over Apr 1) — a leadership-uncertainty catalyst.
• Dec 2025 — Natera patent litigation fully resolved in NeoGenomics' favor (both patents invalid) — removed an existential legal risk to RaDaR/InVisionFirst.
• Feb 2026 — RaDaR ST full clinical launch ($20B+ MRD TAM narrative).
• Apr 2026 — Q1-26 beat + FY26 revenue guide raise, part of the ~3x recovery from the low.
• The re-rating: from $4.72 low (mid-2025) → $7.42 (3/31/26) → ~$15.16 (7/2/26) — roughly a 3.2x move off the bottom on the combination of litigation win + CEO reset + RaDaR-ST + guide raise.

What the market actually reacts to: (1) guidance revisions (the 2025 cut was catastrophic; the 2026 raise was the recovery fuel), (2) reimbursement/coverage + pipeline milestones (RaDaR-ST, Medicare coverage), (3) legal/regulatory de-risking (Natera win up; the unresolved OIG matter is the standing down-risk). It reacts far less to a single revenue print in isolation — this is a "show me the FCF and resolve the overhang" name.

---

Phase C — Judge people & books

Lens 9 · Management

The headline risk: leadership instability. NeoGenomics has had ~4 CEOs in ~4 years.

• CEO lineage: Douglas VanOort (founder-era chairman/CEO, retired as CEO 2021) → Mark Mallon (Apr 2021–Mar 2022) → Christopher M. Smith (Aug 2022–Apr 1, 2025) → Tony Zook (Apr 1, 2025–present). This churn is a genuine governance yellow flag — a company that cannot keep a CEO for a full cycle.
• Current CEO — Tony Zook. Strong pedigree: ex-AstraZeneca EVP Global Commercial Operations (global P&L, ~$30B revenue), ex-CEO Innocoll Pharmaceuticals, and a NeoGenomics board member since 2023 before stepping up — so he knew the company. Archetype = professional commercial operator, not a founder or a scientist. Implication for this stage: the right profile to fix a commercial/reimbursement/execution problem (which is NEO's actual problem), less obviously the profile to drive a scientific-platform leap.
• CFO transition (fresh): long-time CFO Jeff Sherman is retiring; Abhishek Jain joined Jan 12, 2026 and became CFO March 2, 2026. A simultaneous CEO (2025) and CFO (2026) turnover compounds the continuity risk — new top-two leadership both installed inside ~18 months.
• Other execs: Warren Stone (President & COO), Andrew Lukowiak (Chief Innovation Officer).
• Skin in the game / comp: both Smith and Sherman were hired on inducement equity awards (the standard external-hire package); insider ownership is not concentrated (no founder-CEO with a big stake anymore). insider-transactions.csv is not on the shelf, so I can't quantify current insider buying/selling — flag as an open item rather than assert. SBC ran $41.3M in FY2025 (~5.7% of revenue) and $9.6M in Q1-26 — a meaningful, ongoing dilution/comp cost.
• Capital-allocation history — mixed-to-poor. The Inivata (2021, RaDaR) and Pathline (2025, $8.5M, NE-US footprint) deals are strategically coherent, but the ledger also shows value destruction: a $27.8M FY2025 impairment — $11.4M writing off InVisionFirst-Lung intangibles and $15.9M on the Trapelo disposal (sold Dec 2025 for $2.5M upfront + up to $5M contingent, having impaired $3.5M goodwill + $12.4M developed tech). Trapelo and InVisionFirst-Lung were prior-management bets that didn't pan out. ROE/ROIC is negative (accumulated deficit $(433.8)M, persistent net losses) — capital has not compounded. On the positive side, the 2025 balance-sheet move was disciplined: they repaid the $201.3M 2025 Convertible Notes in cash at maturity rather than refinancing dilutively.

Net: a credible new commercial CEO inheriting a company that has churned leadership and destroyed some capital, now tasked with proving operating leverage. Not a "trust the founder" story — a "trust the operator to execute the turnaround" story, with limited track record at this company yet.

Lens 10 · Forensic Red Flags

Acting as a forensic analyst. NeoGenomics is not a fraud-pattern name (clean Deloitte opinion, effective ICFR, no SEC actions), but it carries real accounting-quality and contingency flags that a bull must underwrite.

Income statement:

• GAAP losses are structural, not one-off. Net loss $(88.0)M (2023) → $(78.7)M (2024) → $(108.0)M (2025). The 2025 loss widened despite revenue growth, driven by the $27.8M impairment + $41.3M SBC. "Adjusted EBITDA" of $43.4M (2025) is a heavily-engineered number — it adds back $41.3M SBC, $27.8M impairment, $11.3M IP-litigation, $7.3M acquisition, $3.5M CEO-transition, plus D&A. Strip SBC alone (a recurring cost) and the "adjusted" profitability roughly halves. Treat adj. EBITDA with skepticism; the GAAP loss is the honest number.
• Revenue recognition is the audit's Critical Audit Matter. Deloitte flagged implicit price concessions on clinical revenue — a manual, judgment-heavy estimate of what payers will actually pay, recognized before cash is received — as the critical audit matter. This is the single biggest revenue-quality risk: aggressive concession assumptions would inflate revenue and AR. Not alleged here, but it is the pressure point.

Balance sheet:

• Goodwill + intangibles = ~$811M, ~60% of $1.36B total assets (Goodwill $524.3M + Intangibles net $286.5M). A goodwill-heavy balance sheet that already took a 2025 impairment; a Q3-25 quantitative test passed "by a margin" only. If the growth story stalls, further impairment is a live risk — management explicitly ran quantitative goodwill tests in Q3-25 because indicators suggested fair value might be below carrying value.
• Deferred-tax valuation allowance $100.5M, a three-year cumulative loss position in both the US and UK — management's own language: a cumulative loss is "a significant piece of negative evidence that is difficult to overcome". The company can't recognize its NOLs ($250.8M federal, $253.6M foreign) because it can't yet demonstrate it will be profitable enough to use them. That is a management admission that near-term GAAP profitability is not assured.
• Convertible debt: $345M 2028 Convertible Notes (0.25% coupon, conversion price $66.15, fair value ~$315.7M at Q1-26) — deeply out of the money vs a ~$15 stock, so it will almost certainly be settled in cash/refi at Jan-2028 maturity, not converted. Against $146M cash and negative operating cash flow, the 2028 maturity is a real funding wall the FCF story has to clear (see Lens 13). Capped calls (cap $85.75) are worthless at this price.

Cash flow vs earnings:

• Operating cash flow is barely positive-to-negative: +$5.2M (2025 FY), +$7.0M (2024), but $(8.1)M in Q1-26. The company is essentially not generating free cash after ~$27M/yr capex (guided $30–35M for 2026). The gap between "adj. EBITDA $43M" and "operating cash flow ~$5M" is the tell — SBC and working capital eat most of the "adjusted" profit. This is the crux of the whole thesis: NEO does not yet self-fund.

Regulatory findings (required sub-section):

• SEC EDGAR EFTS: 0 Litigation Releases and 0 AAERs naming NeoGenomics in 2021–2026.
• 10-K Item 3 / Note 15 (the company's own disclosure) — the material overhang: an ongoing OIG (HHS Office of Inspector General) matter. NeoGenomics voluntarily self-reported to the OIG in November 2021 after an internal investigation into whether certain consulting/service agreements complied with federal healthcare fraud-and-abuse laws. As of Q1-2026 the company has accrued an $11.2M reserve for the minimum probable loss — and explicitly states it "is unable to estimate a range of possible loss in excess of the amount reserved," warning that an adverse finding could mean civil/criminal fines, disgorgement, restitution, or exclusion from federal healthcare programs. Exclusion from Medicare/Medicaid would be catastrophic for a lab where ~13%+ of revenue is government-paid — this is the single largest tail risk in the whole file, and it is unquantified and unresolved nearly 5 years after self-reporting.
• Securities litigation (Goldenberg): a Sections 10(b)/20(a) class action (class period Feb-2020–Apr-2022, alleging misstatements re: test menu, operations, and healthcare-law compliance) was DISMISSED WITH PREJUDICE on March 13, 2026 — but the plaintiff appealed to the 2nd Circuit on April 10, 2026. Related derivative suits (Puskarich/Wong/Mellema) are stayed pending the outcome. Directionally positive (dismissed) but not final.
• Non-SEC web search ("NeoGenomics" (FTC OR DOJ OR FDA OR CFPB OR consent decree OR settlement OR fine OR penalty) enforcement): no additional material enforcement action surfaced beyond the self-disclosed OIG matter above.
• Summary: clean auditor + clean SEC record, but a live, unquantified OIG fraud-and-abuse investigation with an $11.2M floor and program-exclusion tail risk, plus a securities case on appeal. The books are not fraudulent; the contingencies are the risk.

---

Phase D — Project & stress-test

Lens 11 · Forward Projection (FY2026 / FY2027 / FY2028)

Built bottom-up from the latest actuals + company guidance. Company FY2026 guide: revenue $797–803M, adj. EBITDA $55–57M. NeoGenomics is GAAP-lossmaking, so an EPS line is close to zero/negative and not the right anchor — the honest forward metric is revenue growth + adjusted EBITDA + the path to positive free cash flow. I project both but weight the FCF-inflection question. Every input labeled; output ``.

Anchors (FY2025 actual): revenue $727.3M, adj. EBITDA $43.4M, GAAP EPS $(0.84), op. cash flow +$5.2M, ~130M shares.

Bull path: RaDaR-ST + NGS drive revenue growth to ~13–15%, adj. EBITDA margin reaches low-teens by FY28, operating cash flow comfortably covers capex and pre-funds the 2028 convert → FCF inflection re-rates the multiple toward the growth cohort. Revenue ~$1.05B+, adj. EBITDA ~$130M by FY28. Bear path: reimbursement pressure + pharma-services decline hold growth to ~7–8%, margin leverage disappoints (supplies/comp keep gross margin ~43%), operating cash flow stays near breakeven, and the OIG matter or a goodwill impairment lands → the stock re-rates down toward legacy-lab-in-secular-decline. Revenue ~$850M, adj. EBITDA ~$60M by FY28.

Brier forecast (not logged — --watchlist breadth mode; log only on genuine base-case commitment per SKILL): the natural scoreable base call would be "NEO FY2026 adjusted EBITDA ≥ $55M (bottom of guide), p≈0.60, resolves 2026-12-31" and "NEO reaches sustained positive quarterly free cash flow before FY2028, p≈0.45." Recorded here as candidates for /thesis to log if promoted; no forecast.ts create run in this unattended sweep.

Lens 12 · Bull vs Bear

Bull case. NeoGenomics is a legitimate, scaled, oncology-only lab trading at a legacy-lab multiple (3.0x EV/Sales) while owning a growth engine (NGS +26%, RaDaR-ST MRD) aimed at a $20B+ TAM growing 30%/yr and <10% penetrated. Four levers: (1) mix-shift operating leverage — NGS/MRD are higher-value than legacy FISH/flow, and management guides EBITDA +27–31% on ~10% revenue; (2) RaDaR-ST, now Medicare-covered for select solid tumors, WES-based, ~100% specificity — a credible entrant into MRD against Natera/Guardant; (3) de-risking — Natera patent win (Dec 2025) and Goldenberg dismissal (Mar 2026) remove two overhangs; (4) a strong new commercial CEO (Zook, ex-AZ ~$30B P&L) exactly suited to a reimbursement/execution turnaround. The Exact Sciences → Abbott take-out at $105/share (~$21B, Mar 2026) proves strategics will pay up for oncology-testing scale — NEO at a $2B EV is a plausible strategic target. If FCF inflects and the multiple moves even halfway toward the growth cohort, the equity re-rates materially.

Bear case (things that could permanently impair): (1) The OIG fraud-and-abuse matter — unresolved since Nov-2021, only an $11.2M floor reserved, with a program-exclusion tail that could impair a chunk of government revenue and, worse, brand/trust with community clients; this is the asymmetric downside. (2) No proven FCF engine — operating cash flow was $(8.1)M in Q1-26 and ~$5M for all of FY25; the company does not self-fund and faces a $345M convert maturity in Jan-2028 against $146M cash; if leverage disappoints, it's a dilution/refi risk. (3) Reimbursement is the whole ballgame and NEO is a price-taker — one adverse CMS/LCD decision compresses the model. (4) Goodwill risk — ~60% of assets are goodwill/intangibles that already took a 2025 write-down and passed the 2025 impairment test only by a margin. Expectations baked into the price: the ~3x move off the low has already priced a successful RaDaR-ST ramp and 2026 leverage delivery — the easy money (litigation-win + CEO-reset + guide-raise) is made.

Pre-mortem (18 months out, thesis broke — what happened?): most likely path — RaDaR-ST adoption is slower than the $20B-TAM narrative implied (MRD reimbursement/coverage expansion is gradual, competition from Natera Signatera and Guardant Reveal is fierce), 2026 EBITDA lands at the low end or misses, operating cash flow stays near breakeven, and then the OIG matter resolves adversely (fine + corporate-integrity agreement). The stock round-trips back toward $8–10, and the "cheap vs Guardant" bull is revealed as a value trap because the growth + FCF never showed up.

Are multiples too high? Not on an absolute EV/Sales basis — 3.0x is cheap for the sector. But the multiple is arguably correct for the fundamentals (11% growth, no FCF, OIG overhang), so "cheap" only pays if the FCF inflection + de-risking actually happen. The bet is not "is it cheap" (it is), it's "will the catalysts convert the cheapness into a re-rating."

Contrarian view (what the market is refusing to see): the bulls chasing the 3x recovery are treating NEO as a mispriced growth name; the contrarian read is that the market's legacy-lab multiple is the honest verdict, and the real, un-priced optionality is strategic M&A (post-Exact/Abbott, a scaled oncology-testing asset at a $2B EV in a consolidating sector is a more likely re-rating path than organic FCF inflection). The name may be worth more to Quest/LabCorp/Roche than to the public market.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case.

• What structurally breaks the model: an adverse OIG resolution with Medicare/Medicaid exclusion or a large disgorgement — self-reported 2021, still open, only $11.2M floor, range "not estimable." A lab that loses federal-program eligibility, or that has to disclose a fraud-and-abuse settlement, damages the community-client trust that is its only real moat. This is the short's dream scenario and it is genuinely on the table.
• Revenue concentration / what shifts: not client-concentrated, but ~29% is third-party reimbursed and 100% is reimbursement-rate-dependent — a CMS Clinical Lab Fee Schedule cut or an unfavorable MRD/NGS coverage decision hits the whole book. The company is a price-taker with no pricing power.
• Why the moat is weaker than bulls think: "comprehensive menu + community relationships" is a service moat, not a structural one. Guardant, Natera and Tempus have proprietary platforms + data-network effects + far bigger R&D budgets; NEO's NGS is competitive but not differentiated, and its MRD (RaDaR) is a fast-follower to Natera's entrenched Signatera. The most dangerous competitor bulls underrate: Natera — same MRD market, ~16x the market cap, an installed Signatera base, and a demonstrated willingness to litigate.
• Worst capital allocation / accounting flags: a $27.8M 2025 impairment on prior-management acquisitions (InVisionFirst-Lung, Trapelo) — a track record of buying assets that get written off. "Adjusted EBITDA" adds back recurring SBC (5.7% of revenue) to manufacture a profitability that GAAP ($(108)M loss) and operating cash flow ($5M) don't support. A $100.5M DTA valuation allowance is management conceding it can't demonstrate future profitability.
• What must hold for today's ~$15 price: RaDaR-ST ramps on schedule, FY26 EBITDA hits guide, operating leverage continues into FY27, OIG resolves without a program-exclusion or nine-figure penalty, and the 2028 convert gets refinanced cleanly. That's a lot of things going right, and the stock has already tripled pricing them in.
• If growth disappoints 20–30%: revenue growth to ~7–8% + margin miss → adj. EBITDA below guide → operating cash flow negative → the legacy-lab multiple compresses further (toward 2x EV/Sales) and the convert maturity becomes a dilution event. Downside to ~$8–10 is very live.
• Single scenario that permanently impairs the business: OIG finding → Medicare/Medicaid exclusion (or a settlement large enough to force a dilutive raise ahead of the 2028 convert). Plausibility: low-probability, high-severity — but 5 years unresolved is itself a signal the matter is non-trivial.

Lens 14 · Management Questions (ordered by information value)

1. OIG matter: it's been ~5 years since you self-reported (Nov 2021) with only an $11.2M floor reserved — what is the realistic timeline to resolution, and can you rule out exclusion from federal healthcare programs as an outcome? (Highest info value — it's the asymmetric tail.)
2. Free cash flow: operating cash flow was ~$5M for all of FY25 and negative in Q1-26 — in which quarter do you expect sustained positive free cash flow after capex, and does that path fully pre-fund the $345M 2028 convertible without equity issuance?
3. RaDaR-ST: what does the 12-month adoption + reimbursement ramp actually look like by tumor type, and how do you win share against an entrenched Natera Signatera and Guardant Reveal?
4. Adjusted EBITDA quality: why should investors credit an "adjusted EBITDA" that adds back ~$40M of recurring stock-based comp — what is the trajectory to GAAP operating profitability?
5. Guidance credibility: after the Aug-2025 cut, what has structurally changed in your forecasting process so the FY26 $797–803M / $55–57M EBITDA guide is dependable?
6. DTA valuation allowance: you carry a $100.5M valuation allowance and a 3-year cumulative loss — what specific milestones would let you release it (i.e., demonstrate durable profitability)?
7. Reimbursement exposure: quantify revenue at risk from a CMS Clinical Lab Fee Schedule cut or an adverse MRD/NGS coverage decision — where are you a price-taker vs. price-setter?
8. Leadership continuity: with a new CEO (2025) and new CFO (2026), how do you convince the market this is the end of the leadership churn (4 CEOs in ~4 years), and what is Tony Zook's 3-year operating plan?
9. Segment economics: you report one segment — what is the gross margin of the NGS/MRD growth engine vs. the legacy FISH/flow base, and how does mix-shift change consolidated margin?
10. Pharma / non-clinical services: this line is a drag on the "macro clinical-trial slowdown" — is it a structural decline or a cyclical trough, and would you consider divesting it?
11. Goodwill: ~60% of assets are goodwill/intangibles and you passed the 2025 test "by a margin" — what revenue/margin scenario triggers another impairment?
12. M&A posture: post-Exact/Abbott, is NeoGenomics a consolidator or a target, and how do you think about the strategic value of a scaled oncology-testing asset?
13. Capital allocation: given the InVisionFirst-Lung and Trapelo write-offs, what is your bar for future M&A vs. organic reinvestment vs. deleveraging?
14. Competitive R&D: your R&D is ~5% of revenue vs. much larger spends at Guardant/Tempus/Natera — how do you stay competitive on assay innovation at that budget?
15. UK operations: Cambridge/UK has driven persistent foreign losses ($(67.6)M pre-tax in 2025) and a full UK valuation allowance — what is the strategic rationale for keeping it, and when does it turn?

---